UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

MARK ONE

Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

for the Quarterly Period ended September 30, 20212022; or

 

Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

for the transition period from ________ to ________

 

WORLD HEALTH ENERGY HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware 000-3025659-2762023
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)

 

1825 NW Corporate Blvd. Suite 110, Boca Raton, FL 33431
(Address of principal executive offices) Zip Code

 

(561) 870-0440

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
N/A N/A N/A

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller repor476,7879tingreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
   Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

 

As of November 22, 2021,14, 2022, 478,789,407,996503,002,741,330 shares of the registrant’s common stock, par value $0.00001 per share, were outstanding.

 

 

 

 

WORLD HEALTH ENERGY HOLDINGS, INC.

Form 10-Q

September 30, 20212022

 

 Page
  
PART I — FINANCIAL INFORMATION 
  
Item 1 – Financial Statements – Unaudited 
  
Condensed Consolidated Balance Sheets – September 30, 20212022 and December 31, 2020202134
  
Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 20212022 and 2020202145
  
Condensed Consolidated Statement of Changes in Stockholders’ Deficit for the three and nine months ended September 30, 20212022 and 2020202156
  
Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 20212022 and 2020202168
  
Notes to Condensed Consolidated Financial Statements79
  
Item 2 – Management’s Discussion and Analysis of Financial Condition and Results of Operations1416
  
Item 3 – Quantitative and Qualitative Disclosures About Market Risk2122
  
Item 4 – Controls and Procedures2122
  
Item 1 – Legal Proceedings2223
  
Item 1A – Risk Factors2223
  
Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds2323
  
Item 3 – Defaults upon Senior Securities2324
  
Item 4 – Mine Safety Disclosures2324
  
Item 5 – Other Information2324
  
Item 6 – Exhibits2324
  
Exhibit Index2324
  
SIGNATURES2425

 

i

WORLD HEALTH ENERGY HOLDINGS, INC.

INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 30, 2022

(UNAUDITED)

2

 

 

WORLD HEALTH ENERGY HOLDINGS, INC.

 

INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

AS OF SEPTEMBER 30, 2021

IN U.S. DOLLARS2022

 

(U.S. dollars except share and per share data)

(UNAUDITED)

TABLE OF CONTENTS

 

 Page
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS:
Interim Condensed Consolidated Balance sheets as of September 30, 2021 (unaudited), and December 31, 20203
Condensed Consolidated Statements of Comprehensive Loss for three and nine months ended September 30, 2021 and 2020 (unaudited)4
Interim Condensed Consolidated Statements of Comprehensive Loss5
Interim Condensed Consolidated Statements of stockholders’ deficit for the three and nine months ended September 30, 2021 (unaudited) and the year ended December 31, 202056
Interim Condensed Consolidated Statements of cash flows for the nine months ended September 30, 2021 and 2020 (unaudited)68
Notes to unauditedInterim condensed consolidated financial statements7- 139 - 15

 

23

 

WORLD HEALTH ENERGY HOLDINGS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(U.S. dollars except share and per share data)

 

  September 30,  December 31, 
  2021  2020 
  (Unaudited)    
A s s e t s        
Current Assets        
Cash and cash equivalents  53,369   359,949 
Accounts receivable, net  24,413   5,086 
Other current assets  277,406   42,178 
T o t a l Current assets  355,188   407,213 
         
Right Of Use asset arising from operating lease  213,184   - 
Long term prepaid expenses  24,775   24,883 
         
Property and Equipment, Net  29,588   26,054 
         
T o t a l assets  622,735   458,150 
         
Liabilities and Shareholders’ Deficit        
Current Liabilities        
Accounts payable  30,369   26,284 
Right Of Use liabilities arising from operating lease  42,986   - 
Other accounts liabilities  1,224,072   496,874 
T o t a l current liabilities  1,297,427   523,158 
         
Liability for employee rights upon retirement  148,654   104,850 
Long term loan from parent company  2,025,049   1,812,704 
Right Of Use liabilities arising from operating lease  178,275   - 
         
T o t a l liabilities  3,649,405   2,440,712 
         
Stockholders’ Deficit        
Preferred stock, par $0.00001, 10,000,000 shares authorized, 5,000,000 shares issued and outstanding as of September 30, 2021 and December 31, 2020.  3,500   3,500 
Series B Convertible Preferred stock, par $0.0001, 3,870,000 shares authorized, 3,870,000 shares issued and outstanding as of September 30, 2021 and December 31, 2020.  2,709   2,709 
Preferred stock, value  3,500   3,500 
Common stock, par $0.00001, 110,000,000,000 shares authorized, 91,989,407,996 shares issued and outstanding at September 30, 2021 and 89,789,407,996 shares issued and outstanding at December 31, 2020.  62,874,586   62,852,586 
Additional paid-in capital  (61,899,883)  (63,339,225)
Foreign currency translation adjustments  (5,495)  (5,495)
Accumulated deficit  (4,002,087)  (1,496,637)
T o t a l stockholders’ deficit  (3,026,670)  (1,982,562)
T o t a l liabilities and stockholders’ deficit  622,735   458,150 
         
  September 30,  December 31, 
  2022  2021 
 (Unaudited)   

(Audited)

 
ASSETS        
Current assets        
Cash and cash equivalents  111,436   46,022 
Accounts receivable, net  20,158   10,022 
Advance on account of investment  -   900,000 
Other current assets  239,686   356,131 
Total current assets  371,280   1,312,175 
         
Operating lease - Right of use asset  177,385   201,518 
Long term prepaid expenses  22,580   25,723 
Property and equipment, net  37,545   27,777 
Funds in respect of employee rights upon termination  28,060   21,182 
Investment in CrossMobile (note 1)  4,835,733   - 
         
Total assets  5,472,583   1,588,375 
         
LIABILITIES AND STOCKHOLDERS’ DEFICIT        
Current liabilities        
Accounts payable  91,038   80,059 
Current long term operating lease liability  43,279   45,756 
Other account liabilities  405,300   638,388 
Total current liabilities  539,617   764,203 
         
Liability for employee rights upon retirement  159,247   157,860 
Long term loan from parent company  2,012,339   2,012,339 
Long term operating lease liability  119,196   173,227 
         
Total liabilities  2,830,399   3,107,629 
         
Stockholders’ deficit        
Preferred stock, par $0.0007, 10,000,000 shares authorized, 5,000,000 shares issued and outstanding as of September 30, 2022 and December 31, 2021.  3,500   3,500 
Series B Convertible Preferred stock, par $0.0007, 3,870,000 shares authorized, 0 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively.  -   - 
Preferred stock, value  -   - 
Common stock, par $0.00001, 750,000,000,000 shares authorized at September 30, 2022 and December 31, 2021. 503,002,741,330 and 488,499,407,996 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively.  66,984,719   66,839,685 
Additional paid-in capital  (49,379,068)  (62,263,494)
Proceeds on account of shares  290,000   - 
Foreign currency translation adjustments  (5,495)  (5,495)
Accumulated deficit  (15,251,472)  (6,093,450)
Total stockholders’ equity (deficit)  2,642,184   (1,519,254)
Total liabilities and stockholders’ deficit  5,472,583   1,588,375 

 

The accompanying notes are an integral part of the condensed consolidated financial statements.

34

 

 

WORLD HEALTH ENERGY HOLDINGS, INC.INC .

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(U.S. dollars except share and per share data)

  2021  2020  2021  2020 
  Nine months ended  Three months ended 
  September 30  September 30 
  2021  2020  2021  2020 
  (Unaudited)  (Unaudited) 
             
Revenues  115,167   52,906   33,717   24,798 
                 
Research and development expenses  (374,561)  (328,529)  (120,701)  (181,175)
General and administrative expenses (Note 4)  (2,195,621)  (227,525)  (1,925,967)  (109,466)
Operating loss  (2,455,015)  (503,148)  (2,012,951)  (265,843)
Financing income (expense), net  (50,435)  6,925   (19,519)  (2,307)
Net loss  (2,505,450)  (496,223)  (2,032,470)  (268,150)
                 
Other comprehensive loss - Foreign currency loss  -   (218)  -   (3,523)
Comprehensive loss  (2,505,450)  (496,441)  (2,032,470)  (271,673)
                 
Loss per share (basic and diluted)  (0.00)  (0.00)  (0.00)  (0.00)

The accompanying notes are an integral part of the condensed consolidated financial statements.

4

WORLD HEALTH ENERGY HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ DEFICIT

(U.S. dollars, except share and per share data)

  Number of Shares  Amount  Number of Shares  Amount  Number of Shares  Amount             
  Preferred Stock  Preferred Stock B  

Common Stock

  Additional paid-in capital  

Foreign currency

translation

adjustments

  Accumulated deficit  Total Company’s stockholders’ deficit 
  Number of Shares  Amount  Number of Shares  Amount  Number of Shares  Amount             
BALANCE AT JANUARY 1, 2020  -   -   3,870,000   2,709   -   -   (2,681)  (5,495)  (623,844)  (629,311)
Effect of Reverse Capitalization                                        
Effect of reverse capitalization share                                        
Issuance of shares                                        
Issuance of shares, share                                        
Issuance of shares in exchange for services                                        
Issuance of shares in exchange for services, share                                        
Share based compensation for services providers                                        
Comprehensive loss for three months ended March 31, 2020  -   -   -   -   -   -   -   5,893   (168,938)  (163,045)
BALANCE AT MARCH 31, 2020 (Unaudited)  -   -   3,870,000   2,709   -   -   (2,681)  398  (792,782)  (792,356)
Effect of Reverse Capitalization  5,000,000   3,500   -   -   89,789,407,996   62,852,586   (63,336,544)  -   -   (480,458)
Comprehensive loss for three months ended June 30, 2020  -   -   -   -   -   -   -   (2,588)   (59,135)  (61,723)
BALANCE AT JUNE 30, 2020 (Unaudited)  5,000,000   3,500   3,870,000   2,709   89,789,407,996   62,852,586   (63,339,225)  (2,190)  (851,917)  (1,334,537)
Comprehensive loss for three months ended September 30, 2020  -   -   -   -   -   -   -   (3,523)   (268,150)  (271,673)
BALANCE AT SEPTEMBER 30, 2020 (Unaudited)  5,000,000   3,500   3,870,000   2,709   89,789,407,996   62,852,586   (63,339,225)  (5,713)  (1,120,067)  (1,606,210)

  Preferred Stock  Preferred Stock B  

Common Stock

  Additional paid-in capital  

Foreign currency

translation

adjustments

  Accumulated deficit  Total Company’s stockholders’ deficit 
  Number of Shares  Amount  Number of Shares  Amount  Number of Shares  Amount             
BALANCE AT JANUARY 1, 2021  5,000,000   3,500   3,870,000   2,709   89,789,407,996   62,852,586   (63,339,225)  (5,495)  (1,496,637)  (1,982,562)
Comprehensive loss for three months ended March 31, 2021  -   -   -   -   -   -   -   -   (266,091)  (266,091)
BALANCE AT MARCH 31, 2021 (Unaudited)  5,000,000   3,500   3,870,000   2,709   89,789,407,996   62,852,586   (63,339,225)  (5,495)  (1,762,728)  (2,248,653)
Comprehensive loss for three months ended June 30, 2021  -   -   -   -   -   -   -   -   (206,889)  (206,889)
BALANCE AT JUNE 30, 2021 (Unaudited)  5,000,000   3,500   3,870,000   2,709   89,789,407,996   62,852,586   (63,339,225)  (5,495)  (1,969,617)  (2,455,542)
Issuance of shares  -   -   -   -   1,700,000,000   17,000   153,000   -   -   170,000 
Issuance of shares in exchange for services  -   -   -   -   500,000,000   5,000   245,000   -   -   250,000 
Share based compensation for services providers (Note 4)  -   -   -   -   -   -   1,041,342   -   -   1,041,342 
Comprehensive loss for three months ended September 30, 2021  -   -   -   -   -   -   -   -   (2,032,470)  (2,032,470)
BALANCE AT SEPTEMBER 30, 2021 (Unaudited)  5,000,000   3,500   3,870,000   2,709   91,989,407,996   62,874,586   (61,899,883)  (5,495)  (4,002,087)  (3,026,670)
                 
  Nine months ended  Three months ended 
  September 30  September 30 
  2022  2021  2022  2021 
  (Unaudited)  (Unaudited) 
             
Revenues  67,480   115,167   23,726   33,717 
                 
Research and development expenses  (354,593)  (374,561)  (111,570)  (120,701)
General and administrative expenses  (377,168)  (736,501)  (106,828)  (466,847)
Share based compensation expenses  (8,474,989)  (1,459,120)  (4,529,664)  (1,459,120)
Operating loss  (9,139,270)  (2,455,015)  (4,724,336)  (2,012,951)
Financing income (expenses), net  45,515   (50,435)  8,881  (19,519)
Loss for the period  (9,093,755)  (2,505,450)  (4,715,455)  (2,032,470)
                 
Equity losses  (64,267)  -   (64,267)    
                 
Net loss  (9,158,022)  (2,505,450)  (4,779,722)  (2,032,470)
                 
Basic and diluted net loss per share  (0.00)  (0.00)  (0.00)  (0.00)
                 
Weighted average number of shares outstanding used in computing basic and diluted net loss per share  

494,351,349,388

   

89,863,034,370

   

501,589,697,852

   

90,007,886,257

 

 

The accompanying notes are an integral part of the condensed consolidated financial statements.

 

5

 

 

WORLD HEALTH ENERGY HOLDINGS, INC.

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

(U.S. dollars, except share and per share data)

                                             
  Preferred Stock, $0.0007, Par Value  Preferred Stock B, $0.0007, Par Value  

Common Stock,

$0.0007, Par Value

  Additional  Proceeds on   Foreign currency      Total Company’s   
   Number of Shares   Amount   Number of Shares   Amount   Number of Shares   Amount   paid-in capital   account of shares   

translation

adjustments

   Accumulated deficit   stockholders’ deficit 
BALANCE AS OF JANUARY 1, 2022         5,000,000   3,500                       -   -   488,499,407,996   66,839,685   (62,263,494)                  -   (5,495)  (6,093,450)  (1,519,254)
Issuance of shares  -   -   -   -   2,840,000,000   28,400   255,600   -   -   -   284,000 
Share based payment to service providers  -   -   -   -   -   -   1,310,239   -           1,310,239 
Proceeds on account of shares  -   -   -   -   -   -   -   290,000   -   -   290,000 
Net loss  -   -   -   -   -   -   -   -   -   (1,636,796)  (1,636,796)
BALANCE AS OF MARCH 31, 2022 (Unaudited)  5,000,000   3,500   -   -   491,339,407,996   66,868,085   (60,697,655)  290,000   (5,495)  (7,730,246)  (1,271,811)
Issuance of shares  -   -   -   -   1,633,333,334   16,333   310,917   (40,000)  -   -   287,250 
Share based payment to employees and service providers  -   -   -   -   30,000,000   300   2,457,605   -   -   -   2,457,905 
Net loss  -   -   -   -   -   -   -   -   -   (2,741,504)  (2,741,504)
BALANCE AS OF JUNE 30, 2022 (Unaudited)  5,000,000   3,500   -   -   493,002,741,330   66,884,719   (57,929,134)  250,000   (5,495)  (10,471,750)  (1,268,160)
Issuance of shares for CrossMobile investment  -   -   -   -   10,000,000,000   100,000   3,900,000   -   -   -   4,000,000 
Share based payment to employees and service providers  -   -   -   -   -   -   4,650,066   -   -   -   4,650,066 
Proceeds on account of shares  -   -   -   -   -   -   -   40,000   -   -   40,000 
Net loss  -   -   -   -   -   -   -   -   -   (4,779,722)  (4,779,722)
BALANCE AS OF SEPTEMBER 30, 2022 (Unaudited)  5,000,000   3,500   -   -   503,002,741,330   66,984,719   (49,379,068)  290,000   (5,495)  (15,251,472)  2,642,184

The accompanying notes are an integral part of the condensed consolidated financial statements.

6

WORLD HEALTH ENERGY HOLDINGS, INC.

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

(U.S. dollars, except share and per share data)

                                         
  Preferred Stock, $0.0007, Par Value  Preferred Stock B, $0.0007, Par Value  

Common Stock,

$0.0007, Par Value

  Additional  

Foreign currency

    Total Company’s 
  Number of Shares  Amount  Number of Shares  Amount  Number of Shares  Amount  paid-in capital   translation adjustments   Accumulated deficit   stockholders’ deficit  
BALANCE AT JANUARY 1, 2021  5,000,000   3,500   3,870,000   2,709   89,789,407,996   62,852,586   (63,339,225)  (5,495)  (1,496,637)  (1,982,562)
Net loss  -   -   -   -   -   -   -   -   (266,091)  (266,091)
BALANCE AT MARCH 31, 2021 (Unaudited)  5,000,000   3,500   3,870,000   2,709   89,789,407,996   62,852,586   (63,339,225)  (5,495)  (1,762,728)  (2,248,653)
                                         
Net loss  -   -   -   -   -   -   -   -   (206,889)  (206,889)
BALANCE AT JUNE 30, 2021 (Unaudited)  5,000,000   3,500   3,870,000   2,709   89,789,407,996   62,852,586   (63,339,225)  (5,495)  (1,969,617)  (2,455,542)
Issuance of shares  -   -   -   -   1,700,000,000   17,000   153,000   -   -   170,000 
Issuance of shares in exchange for services  -   -   -   -   500,000,000   5,000   245,000   -   -   250,000 
Share based compensation for services providers  -   -   -   -   -   -   1,041,342   -   -   1,041,342 
Net loss  -   -   -   -   -   -   -   -   (2,032,470)  (2,032,470)
BALANCE AT SEPTEMBER 30, 2021 (Unaudited)  5,000,000   3,500   3,870,000   2,709   91,989,407,996   62,874,586   (61,899,883)  (5,495)  (4,002,087)  (3,026,670)

The accompanying notes are an integral part of the condensed consolidated financial statements.

7

WORLD HEALTH ENERGY HOLDINGS, INC.

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(U.S. dollars except)

 

  2021  2020 
  Nine months ended 
  September 30, 
  2021  2020 
  (Unaudited) 
CASH FLOWS FROM OPERATING ACTIVITIES:        
Net loss for the period  (2,505,450)  (496,223)
Adjustments required to reconcile net loss for the period to net cash used in operating activities:        
Depreciation and amortization  35,119   29,775 
Share based payment to a service providers (Note 4)  1,069,120  - 
Interest on lease liability  25,090   - 
Increase in liability for employee rights upon retirement  43,804   34,950 
Increase in accounts receivable  (19,327)  (5,956)
Increase in other current assets  (11,264)  (15,029)
Increase in accounts payable  4,085   5,183 
Increase in other accounts liabilities  727,199   47,351 
Net cash used in operating activities  (631,624)  (399,949)
         
CASH FLOWS FROM INVESTING ACTIVITIES:        
Loans granted to related parties  (1,634)  (242,091)
Purchase of property and equipment  (8,931)  (9,218)
Net cash used in investing activities  (10,565)  (251,309)
         
CASH FLOWS FROM FINANCING ACTIVITIES:        
Payments of lease liability  (46,735)  (21,474)
Proceeds from stock issued for cash  170,000   - 
Loan received from parent company  212,345   408,988 
Net cash provided by financing activities  335,610   387,514 
         
EFFECT OF EXCHANGE RATES ON CASH AND CASH EQUIVALENTS  -   (1,567)
         
DECREASE IN CASH AND CASH EQUIVALENTS  (306,580)  (265,311)
         
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD  359,949   359,461 
         
CASH AND CASH EQUIVALENTS AT END OF PERIOD  53,369   94,150 
         
Supplemental disclosure of cash flow information:        
Non cash transactions:        
Initial recognition of operating lease right-of-use assets  242,906   - 
Initial recognition of operating lease liability  (242,906)  - 
Share base compensation to a service provider  (250,000)  - 

         
  Nine months ended 
  September 30, 
  2022  2021 
  (Unaudited) 
CASH FLOWS FROM OPERATING ACTIVITIES:        
Net loss for the period  (9,158,022)  (2,505,450)
Adjustments required to reconcile net loss for the period to net cash used in operating activities:        
Depreciation  8,030   35,119 
Increase (decrease) in liability for employee rights upon retirement  1,387   43,804 
Share based compensation  8,474,989   1,459,120 
Equity losses  64,267   - 
Increase in accounts receivable  (10,136)  (19,327)
Increase in other current assets  (92,556)  (11,264)
Increase in accounts payable  10,979   4,085 
Increase (decrease) in other accounts liabilities  (117,284)  315,553 
Net cash used in operating activities  (818,346)  (678,360)
         
CASH FLOWS FROM INVESTING ACTIVITIES:        
Loans received from (granted to) related parties  7,186   (1,634)
Proceeds from related parties  -   (8,931)
Increase in asset for employee rights upon retirement  (6,878)  - 
Purchase of property and equipment  (17,798)  - 
Net cash used in investing activities  (17,490)  (10,565)
         
CASH FLOWS FROM FINANCING ACTIVITIES:        
Proceeds from stock issued for cash  611,250   170,000 
Proceeds on account of shares  290,000   - 
Loan received from parent company  -   212,345 
Net cash provided by financing activities  901,250   382,345 
         
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS  65,414   (306,580)
         
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD  46,022   359,949 
         
CASH AND CASH EQUIVALENTS AT END OF PERIOD  111,436   53,369 
         
Supplemental disclosure of cash flow information:        
Non cash transactions:        
Issuance of shares for future services  83,333   - 
Initial recognition of operating lease  -   242,906 
Issuance of shares for the acquisition of investee  4,000,000   (242,906)

 

The accompanying notes are an integral part of the condensed consolidated financial statement

68

 

 

WORLD HEALTH ENERGY HOLDINGS, INC.INC .

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

 

NOTE 1 GENERAL

 

A.Operations
World Health Energy Holdings, Inc., (the “Company” or “WHEN”), was formed on May 21, 1986, under the laws of the State of Delaware. The Company has invested in and abandoned a variety of software programs that it strove to commercialize.
UCG, INC. (the “UCG”) was incorporated on September 13, 2017, under the laws of the State of Florida. The Company wholly-owns the issued and outstanding shares of RNA Ltd. (Hereinafter: “RNA”).
RNA is primarily a research and development company that has been performing software design work for UCG in the field of cybersecurity under the terms of development agreement between UCG and RNA. UCG is primarily engaged in the marketing and distribution of cybersecurity related products.
In anticipation of the transaction contemplated under the Merger Agreement, SG 77 Inc. a Delaware Corporation and a wholly-owned subsidiary of UCG (“SG”), was incorporated on April 16, 2020 and all of the cybersecurity rights and interests held by UCG, including the share ownership of RNA, were assigned to SG.
On October 7, 2021, the Company filed an amendment (the “Amendment”) to its Certificate of Incorporation, as amended, to increase the Company’s authorized share capital and to change the par value of the Company’s Common Stock. The Amendment increased the Company’s authorized share capital to 750,000,000,000 shares of common stock (from 110,000,000,000 shares) and changed the par value of the common stock to $0.00001 per share (from $0.0007). The Amendment was effective retroactive to September 28, 2021.
B.Merger Transaction
On April 27, 2020, the Company completed a reverse triangular merger pursuant to the Agreement and Plan of Merger (the “Merger Agreement”) among WHEN, R2GA, Inc., a Delaware corporation and a wholly owned subsidiary of WHEN (“Sub”), UCG, SG, and RNA. Under the terms of the Merger Agreement, R2GA merged with SG, with SG remaining as the surviving corporation and a wholly-owned subsidiary of the WHEN (the “Merger”). The Merger was effective as of April 27, 2020 whereby SG became a direct and wholly owned subsidiary of WHEN and RNA indirect wholly owned subsidiary of the Company. Each of Gaya Rozensweig and George Baumeohl, directors of the Company, are also the sole shareholders and directors of the Company.
As consideration for the Merger, WHEN issued to UCG 3,870,000 Series B Convertible Preferred Stock, par value $0.0007 per share, of WHEN (the “Series B Preferred Shares”). Each share of the Series B Preferred Shares will automatically convert into 100,000 shares of WHEN’s common stock, par value $0.0007 (the “Common Stock”), for an aggregate amount of 387,000,000,000 shares of WHEN’s Common Stock, upon the filing with the Secretary of State of Delaware of an amendment to WHEN’s certificate of incorporation increasing the number of authorized shares of Common Stock that the Company is authorized to issue from time to time.
The Company, collectively with SG, Sub and RNA are hereunder referred to as the “Group”.

 

World Health Energy Holdings, Inc., (the “Company” or “WHEN”), was formed on May 21, 1986, under the laws of the State of Delaware. The Company has invested in and abandoned a variety of software programs that it strove to commercialize.

UCG, INC. (the “UCG”) was incorporated on September 13, 2017, under the laws of the State of Florida. The Company wholly-owns the issued and outstanding shares of RNA Ltd. (Hereinafter: “RNA”).

RNA is primarily a research and development company that has been performing software design work for UCG in the field of cybersecurity under the terms of development agreement between UCG and RNA. UCG is primarily engaged in the marketing and distribution of cybersecurity related products.

In anticipation of the transaction contemplated under the Merger Agreement, SG 77 Inc. a Delaware Corporation and a wholly-owned subsidiary of UCG (“SG”), was incorporated on April 16, 2020 and all of the cybersecurity rights and interests held by UCG, including the share ownership of RNA, were assigned to SG.

The Company, collectively with RNA are hereunder referred to as the “Group”.

CrossMobile investment agreement

On March 22, 2022 the Company, CrossMobile CrossMobile Sp. z o.o, a company formed under the laws of Poland (“CrossMobile”) and the shareholders of CrossMobile (of which Mr. Giora Rosenzweig, held 40.67% and Mr. George Baumeohl held 3.33%, of the issued preferred share capital of CrossMobile), entered into an Investment Agreement (the “Agreement”) pursuant to which the Company is to purchase 26% of the outstanding common share capital of CrossMobile on a fully diluted basis, in consideration of the issuance by the Company to CrossMobile of 10,000,000,000 restricted shares of Company common stock (the “Initial Investment”). The preferred share capital of CrossMobile provides certain privileges, including the right to participate in CrossMobile shareholder meetings at a rate of two votes for each preferred share and preference as to distribution of dividends at a rate equal to twice the dividends distributed to the holders of the common shares in CrossMobile

CrossMobile filed an application with the Polish Companies Registrar on June 22, 2022 to increase CrossMobile’s share capital in order to effectuate the issuance to WHEN of the CrossMobile ordinary shares representing 26% of the CrossMobile equity interest to WHEN and to register the issuance to CrossMobile of the 10,000,000,000 WHEN shares in consideration thereof. The Companies Registrar approved the requested actions on July 22, 2022 and published on August 1, 2022. The approval and registration by the Polish Companies Registrar is required under local law for CrossMobil to issue to WHEN the CrossMobile ordinary shares representing 26% of CrossMobile. In anticipation of the approval of the increase in the share capital of CorssMobile, WHEN issued to Crossmobile on July 13, 2022 the 10,000,000,000 WHEN shares. Upon the registration of the Company shareholdings in CrossMobile the closing of the Initial Investment will be deemed to have occurred.

CrossMobile is a licensed mobile virtual network operator (“MVNO”) in Poland, providing the necessary licenses and key infrastructure in the EU. With its involvement in CrossMobile, the Company expects to provide advanced cybersecurity solutions and other next-generation value-added services to CrossMobile’s future product offerings.

In addition, through January 22, 2024, the Company has the option to purchase additional shares of CrossMobile, such that following such additional purchase, the Company shall hold approximately 51% of CrossMobile’s outstanding share capital on a fully diluted basis. In the event the Company shall choose to exercise the option, the Company shall issue such number of restricted shares of common stock of the Company calculated based on pre-money valuation of CrossMobile as determined by an independent appraiser agreed between the Company and CrossMobile. See note 5(1).

79

 

WORLD HEALTH ENERGY HOLDINGS, INC.

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

 

NOTE 1 – GENERAL (continue)

The transaction was accounted for as a reverse asset acquisition in accordance with generally accepted accounting principles in the United States of America (“GAAP”). Under this method of accounting, SG was deemed to be the accounting acquirer for financial reporting purposes. This determination was primarily based on the facts that, immediately following the Merger: (i) SG’s stockholders owned a substantial majority of the voting rights in the combined company, (ii) SG designated a majority of the members of the initial board of directors of the combined company, and (iii) SG’s senior management holds all key positions in the senior management of the combined company. As a result of the Recapitalization Transaction, the shareholders of SG received the largest ownership interest in the Company, and SG was determined to be the “accounting acquirer” in the Recapitalization Transaction. See also Note 5 (Subsequent Events)
As a result, the historical financial statements of the Company were replaced with the historical financial statements of SG. The number of shares prior to the reverse capitalization have been retroactively adjusted based on the equivalent number of shares received by the accounting acquirer in the Recapitalization Transaction.
C.Board and Shareholder Authority for Reverse Stock Split
On June 21, 2021, Company’s stockholders approved an amendment to the Company’s Certificate of Incorporation (the “Reverse Stock Split Certificate of Amendment”) in order to effect a reverse stock split of the Company’s common stock pursuant to a range of between 1,000-to-1 and 15,000-to-1 (the “Reverse Stock Split”), when and as determined by the Company’s Board of Directors. Pursuant to the Reverse Stock Split, each one thousand or fifteen thousand shares of common stock, or any other figure within that range, as shall be determined by the Board of Directors at a later time, will be automatically converted, without any further action by the stockholders, into one share of common stock. The Reverse Stock Split Certificate of Amendment will be effective upon receipt of approval from the Financial Industry Regulatory Authority (“FINRA”) for the Reverse Stock Split and the filing with the Secretary of the State of Delaware. As of the date of this report, the Board of Directors has not determined any particular range for the Reverse Stock Split and no application has been presented to FINRA.
D.B.Going concern uncertainty
Since inception, the Group has devoted substantially all its efforts to research and development. The Group is still in its development stage and the extent of the Group’s future operating losses and the timing of becoming profitable, if ever, are uncertain. As of September 30, 2021, the Group had $53,369 of cash and cash equivalents, net losses of $2,505,450, accumulated deficit of $4,002,087, and a negative working capital of $942,239.
The Group will need to secure additional capital in the future in order to meet its anticipated liquidity needs primarily through the sale of additional Common Stock or other equity securities and/or debt financing. Funds from these sources may not be available to the Group on acceptable terms, if at all, and the Group cannot give assurance that it will be successful in securing such additional capital (see Note 3 in respect to subscription agreements signed between August and October 2021).
These conditions raise substantial doubt about the Company’s ability to continue to operate as a “going concern.” The Company’s ability to continue operating as a going concern is dependent on several factors, among them is the ability to raise sufficient additional funding.

Since inception, the Group has devoted substantially all its efforts to research and development. The Group is still in its development stage and the extent of the Group’s future operating losses and the timing of becoming profitable, if ever, are uncertain. As of September 30, 2022, the Group had $111,436 of cash and cash equivalents, accumulated deficit of $15,251,472, negative working capital of $168,337 and net losses of $9,158,022 during the nine months ended September 30, 2022.

The Group will need to secure additional capital in the future in order to meet its anticipated liquidity needs primarily through the sale of additional Common Stock or other equity securities and/or debt financing. Funds from these sources may not be available to the Group on acceptable terms, if at all, and the Group cannot give assurance that it will be successful in securing such additional capital (see Note 3 in respect to subscription agreements signed during 2022).

These conditions raise substantial doubt about the Company’s ability to continue to operate as a “going concern.” The Company’s ability to continue operating as a going concern is dependent on several factors, among them is the ability to raise sufficient additional funding.

The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

C.COVID-19

 

In early 2020, the World Health Organization declared the rapidly spreading coronavirus disease (COVID-19) outbreak a pandemic. This pandemic has resulted in governments worldwide enacting emergency measures to combat the spread of the virus. The Company considered the impact of COVID-19 on its operations and determined that there were no material adverse impacts on the Company’s results of operations and financial position as of September 30, 2022. These estimates may change, as new events occur and additional information is obtained.

810

 

WORLD HEALTH ENERGY HOLDINGS, INC.INC .

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

E.Risk factors
The Group face a number of risks, including uncertainties regarding finalization of the development process, demand and market acceptance of the Group’s products, the effects of technological changes, competition and the development of products by competitors. Additionally, other risk factors also exist, such as the ability to manage growth and the effect of planned expansion of operations on the Group’s future results. In addition, the Group expects to continue incurring significant operating costs and losses in connection with the development of its products and increased marketing efforts. As mentioned above, the Group has not yet generated significant revenues from its operations to fund its activities, and therefore the continuance of its activities as a going concern depends on the receipt of additional funding from its current stockholders and investors or from third parties.

 

NOTE 2- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION

 

Unaudited Interim Financial Statements

 

The accompanying unaudited interim condensed consolidated financial statements include the accounts of the Company and its subsidiary,have been prepared in accordance with U.S. generally accepted accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q.10-Q

and Article 10 of U.S. Securities and Exchange Commission Regulation S-X. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the financial statements presented herein have not been audited by an independent registered public accounting firm but include all material adjustments (consisting of normal recurring adjustments) which are, in the opinion of management,considered necessary for a fair statement of the financial condition, results of operations and cash flows for the nine-months ended September 30, 2021. However, these results are not necessarily indicative of results for any other interim period or for the year ended December 31, 2021. The preparation of financial statements in conformity with GAAP requires the Company to make certain estimates and assumptions for the reporting periods covered by the financial statements. These estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses. Actual amounts could differ from these estimates.

Certain information and footnote disclosures normally included in financial statements in accordance with generally accepted accounting principlespresentation have been omitted pursuantincluded (consisting only of normal recurring adjustments except as otherwise discussed). For further information, reference is made to the rules of the U.S. Securities and Exchange Commission (“SEC”). These financial statements should be read in conjunction with theconsolidated financial statements and notesfootnotes thereto containedincluded in the Company’s Annual Report on published on the OTCIQ Alternative Reporting System,Form 10-K for the year ended December 31, 2021.

Operating results for the three months and nine months ended September 30, 2022, are not necessarily indicative of the results that may be expected for the year ending December 31, 2022.

 

Principles of Consolidation

 

The consolidated financial statements are prepared in accordance with US GAAP. The consolidated financial statements of the Company include the Company and its wholly-owned and majority-owned subsidiaries. All inter-company balances and transactions have been eliminated.

Use of Estimates

 

The preparation of unaudited condensed consolidated financial statements in conformity with accounting principles generally accepted in the United StatesGAAP requires management to make estimates and assumptions that affect the amounts reported amounts of assets and liabilities, certain revenues and expenses, and disclosure of contingent assets and liabilities as of the date ofin the financial statements.statements and accompanying notes. Actual results could differ from those estimates. As applicable to these

Recent Accounting Pronouncements

Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s condensed financial statements, the most significant estimates and assumptions relate to the going concern assumptions, stock based compensation and estimations in respect of service period upon issuance of shares to services provider.statements.

 

911

 

WORLD HEALTH ENERGY HOLDINGS, INC.

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

 

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (continue)3

LeasesCOMMON STOCK

 

The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, other current liabilities, and operating lease liabilities in our consolidated balance sheets.

ROU assets represent Company’s right to use an underlying asset for the lease term and lease liabilities represent Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, the Company generally uses the incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement date. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

Stock-based compensation

The Company measures and recognizes the compensation expense for all equity-based payments to employees based on their estimated fair values in accordance with ASC 718, “Compensation-Stock Compensation”. Share-based payments including grants of stock options are recognized in the statement of comprehensive loss as an operating expense based on the fair value of the award at the date of grant. The fair value of stock options granted is estimated using the Black-Scholes option-pricing model. The Company has expensed compensation costs, net of estimated forfeitures, applying the accelerated vesting method, over the requisite service period or over the implicit service period when a performance condition affects the vesting, and it is considered probable that the performance condition will be achieved.

Share-based payments awarded to consultants (non-employees) are accounted for in accordance with ASC Topic 505-50, “Equity-Based Payments to Non-Employees”.

Recent Accounting Pronouncements

In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU 2020-06”). The guidance in ASU 2020-06 simplifies the accounting for convertible debt and convertible preferred stock by removing the requirements to separately present certain conversion features in equity. In addition, the amendments in the ASU 2020-06 also simplify the guidance in ASC Subtopic 815-40, Derivatives and Hedging: Contracts in Entity’s Own Equity, by removing certain criteria that must be satisfied in order to classify a contract as equity, which is expected to decrease the number of freestanding instruments and embedded derivatives accounted for as assets or liabilities. Finally, the amendments revise the guidance on calculating earnings per share, requiring use of the if-converted method for all convertible instruments and rescinding an entity’s ability to rebut the presumption of share settlement for instruments that may be settled in cash or other assets.

10

WORLD HEALTH ENERGY HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

The amendments in ASU 2020-06 are effective for the Company for fiscal years beginning after December 15, 2021. Early adoption is permitted. The guidance must be adopted as of the beginning of the fiscal year of adoption. The Company is currently evaluating the impact of this new guidance, but does not expect it to have a material impact on its financial statements.

NOTE 3 – COMMON STOCK

On August 31, 2021 the Company issued 500,000,000 shares of common stock, par value $0.00001, to its legal advisor in respect of consulting services related to assisting the Company with its follow-on-offering registration statements. The Company estimated the fair value of the shares issued based on the share price at the agreement date (which was $0.0005), at $250,000 thousand of which $27,778 were recorded as share based compensation expenses in the three month ended September 30,2021, and the remaining was recorded as other current assets and will be expensed over the estimated remaining consulting services. Per the agreement, the Company committed to pay the Consultant additional $350,000 upon certain specified milestones which have not been met as of balance sheet date.

Between August and October 2021, the Company and certain investors entered into subscription agreements for a private placement of units of the Company securities (the 2021 Private Placements”) where each unit (a “Unit” and collectively the “Units”) is comprised of (i) one (1) share of the Company’s Common Stock and (ii) one common stock purchase warrant to purchase an additional share of the Company’s Common Stock through the second anniversary thereof at a per share exercise price of $0.0002.$0.0002. The price per unit is $0.0001.$0.0001. Subscription agreements for an aggregate of $900,000 provide that the investors are to remit the subscription proceeds at the time of investment and in three month intervals thereafter, in each case in amounts equal to 20% of their committed amounts. Subscription agreements for a total of $170,000 were remitted atDuring the time of execution.Throughnine months ended September 30, 2021,2022, the Company received a total of $170,000 151,250from on account of these subscription proceeds and in consideration thereof issued 1,700,000,000 1,140,000,000shares of Common Stock and warrants for an additional 1,700,000,000 1,140,000,000shares of Common Stock. See Note 5 (Subsequent Events”)Stock and the balance is presented as proceeds on account of shares.

 

During the nine months ended September 30, 2022, the Company and certain investors entered into subscription agreements for a private placement of units of the Company securities in an aggregated amount of $500,000, where each unit (a “Unit” and collectively the “Units”) is comprised of (i) one (1) share of the Company’s Common Stock and (ii) one common stock purchase warrant to purchase an additional share of the Company’s Common Stock through the second anniversary thereof at a per share exercise price of $0.0002. The price per unit is $0.0001. As part of the subscription agreements, CrossMobile undertook to issue the investors up to 5% of the issued and outstanding share capital of CrossMobile. During the nine months ended September 30, 2022, the Company received a total of $500,000 on account of these subscription and in consideration thereof issued 2,500,000,000 shares of Common Stock and warrants for an additional 2,500,000,000 shares of Common Stock and the balance is presented as proceeds on account of shares.

In May 2022, the Company and certain investors entered into subscription agreements for a private placement of units of the Company securities (the May 2022 Private Placements”) in an aggregated amount of $250,000, where each unit (a “Unit” and collectively the “Units”) is comprised of (i) one (1) share of the Company’s Common Stock and (ii) one common stock purchase warrant to purchase an additional share of the Company’s Common Stock for a one year period at a per share exercise price of $0.0006. The price per unit is $0.0003. In consideration thereof, the Company issued 833,333,334 shares of Common Stock and warrants for an additional 833,333,334 shares of Common Stock.

On May 19, 2022 the Company issued 30,000,000 share of the Company’s Common Stock to a service provider in exchange for certain tax services. The Company estimated the value of the shares issued at $9,000 based on the share price of the Company as of the issuance date.

On August 10, 2022, the Company entered into an agreement with a consultant with a term of 12 months under which it undertook to issue to the Consultant 300,000,000 restricted stock for investor relations services.

12

WORLD HEALTH ENERGY HOLDINGS, INC .

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

NOTE 4- STOCK OPTIONS

 

On June 21, 2021, the board of directors of the Company approved the 2021 Equity Incentive Plan (the “2021 Plan”) pursuant to which the Company may issue awards, from time to time, consisting of non-qualified stock options, restricted stock grants and restricted stock units. In addition, stock option awards that qualify under Section 102 of the Israeli Tax Ordinance (New Version) 1961 (the “ITO”), and/or under Section 3(i) of the ITO, may be granted.

 

On June 28,Mr. Tromer, the CEO of CrossMobile, was appointed to the Company’s advisory board in February 2022. In connection with his service on the advisory board, on February 14, 2022, he was awarded options under the Company’s 2021 the Board of Directors of the Company approved the issuance of optionsEquity Incentive Plan to purchase 6,800,000,0006,000,000,000 shares of the Company’s Common Stockcommon stock, at a per share exercise price of $0.0001 per share, which the exercise price for all grants to three membersdate to member of its advisory board, under the Company’s 2021 Plan. Options to purchaseadvisory board. Mr. Tromer’s options vest as follows: 6,800,000,00025% (i.e., 1,500,000,000) option shares of Common Stock shall vest in four annual equal installments, with the first installment of Options vesting on the first anniversary of the grant date, withappointment to the advisory board and the balance in increments of the Options vesting over the400,000,000 shares on each subsequent three (3) month periods following the first anniversary , and shall be exercisable for an exercise price of $0.001 per share.anniversary.

 

The fair value of the options was determined using the Black-Scholes pricing model, assuming a risk free rate of 0.271.85%, a volatility factor of 342397%, dividend yields of 0% and an expected life of 4 6.25years and was estimated at $5,436,0002,400,000.

On January 1, 2022, the Company granted options to purchase 400,000,000 shares of the Company’s Common Stock to a member of its advisory board, under the Company’s 2021 Plan. Options to purchase 100,000,000 shares of Common Stock shall vest on the first anniversary of the agreement and the remaining options shall vest quarterly, over additional 3 years

The fair value of the options was determined using the Black-Scholes pricing model, assuming a risk free rate of 1.12%, a volatility factor between 391%, dividend yields of 0% and an expected life of 6.25 years and was estimated at $200,000.

On May 15, 2022, the Company granted options under the 2021 Plan (2021) to directors, employees and service providers to purchase an aggregate of 34,900,000,000 shares of Common Stock exercisable at a per share exercise price of $0.0001. Of the options granted, 5,000,000,000 were issued to CEO. The options vest on an annual basis with 25% of the option grant vesting on each anniversary of the option grant. Following vesting the options are exercisable through the sixth month anniversary following the last instalment vesting date.

The fair value of the options was determined using the Black-Scholes pricing model, assuming a risk free rate of 2.84%, a volatility factor of 305.1%, dividend yields of 0% and an expected life of 6.25 years and was estimated at $13,959,141.

On September 18, 2022, the Company granted options under the 2021 Plan (2021) to its Chief strategic affairs to purchase an aggregate of 10,000,000,000 shares of Common Stock exercisable at a per share exercise price of $0.0001. Of the options granted, 5,000,000,000 were immediately vested and the remaining shall vest on 4 annual equal instalments commencing May 15, 2023.

The fair value of the options was determined using the Black-Scholes pricing model, assuming a risk free rate of 3.62%, a volatility factor of 306.5%, dividend yields of 0% and an expected life of 5.54 years and was estimated at $3,999,451.

13

WORLD HEALTH ENERGY HOLDINGS, INC .

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

NOTE 4 - STOCK OPTIONS (continue)

 

The following table presents the Company’s stock option activity during the nine months ended September 30, 2021:2022:

SCHEDULE OF STOCK OPTION ACTIVITY

 Number of Options Weighted Average Exercise Price  Number of Options Weighted
Average
Exercise Price
 
Outstanding at December 31,2020  -   - 
Outstanding at December 31,2021  6,800,000,000   0.0001 
Granted  6,800,000,000   0.001   6,400,000,000   0.0001 
Exercised  -   -   -   - 
Forfeited or expired  -   -   -   - 
Outstanding at September 30,2021  6,800,000,000   0.001 
Number of options exercisable at September 30, 2021  -   - 
Outstanding at March 31,2022  13,200,000,000   0.0001 
Granted  34,900,000,000   0.0001 
Exercised  -   - 
Forfeited or expired  -   - 
Outstanding at June 30,2022  48,100,000,000   0.0001 
Granted  10,000,000,000   0.0001 
Exercised  -   - 
Forfeited or expired  -   - 
Outstanding at September 30,2022  58,100,000,000   0.0001 
Number of options exercisable at September 30, 2022  7,125,000,000   0.0001 

 

The aggregate intrinsic value of the awards outstanding as of September 30, 20212022 is zero.11,620,000. These amounts represent the total intrinsic value, based on the Company’s stock price of $0.00060.0003 as of September 30, 2021,2022, less the weighted exercise price. This represents the potential amount received by the option holders had all option holders exercised their options as of that date.

 

The stock options outstanding as of September 30, 2022, have been separated into exercise prices, as follows:

SCHEDULE OF STOCK OPTIONS OUTSTANDING RANGE OF EXERCISE PRICE

Exercise price  Stock options
outstanding
  Weighted average remaining
contractual life –
years
  Stock options vested 
   As of September 30, 2022 
 0.0001   58,100,000,000   3.49   7,125,000,000 
     58,100,000,000   3.49   7,125,000,000 

The stock options outstanding as of December 31, 2021, have been separated into exercise prices, as follows:

SCHEDULE OF STOCK OPTION OUTSTANDING RANGE OF EXERCISE PRICE 

Exercise price  Stock options outstanding  Weighted average remaining contractual life – years  Stock options vested 
   As of September 30, 2021 
 0.001   6,800,000,000   3.75   - 
     6,800,000,000   3.75   - 
Exercise price  Stock options
outstanding
  Weighted average
remaining
contractual life –
years
  Stock options vested 
   As of December 31, 2021 
 0.0001   6,800,000,000   3.49   - 
     6,800,000,000   3.49   - 

 

Compensation expense recorded by the Company in respect of its stock-based compensation awards for the period of nine and three months ended September 30, 20212022 was $1,041,3428,622,640 and are included in General and Administrative expenses in the Statements of Operations.

The Company had committed to issue 3,900,000,000 to a consultant for his past business development services. The Company estimated the fair value of the commitment at $390,000. The commitment was recorded as credit to Other accounts liabilities and debit to Share based compensation expenses.

 

As of September 30, 2022, there was $NOTE 5 – RELATED PARTIES15,212,104 million of total unrecognized compensation cost related to nonvested share-based compensation arrangements granted under the employee share option plan.

A.Transactions and balances with related parties

SCHEDULE OF RELATED PARTY EXPENSES

  2021  2020  2021  2020 
  

Nine months ended

September 30

  

Three months ended

September 30

 
  2021  2020  2021  2020 
             
General and administrative expenses:                
Salaries and fees to officers  92,849   81,377   34,056   51,791 
                 
Research and development expenses:                
Salaries and fees to officers  61,921   46,779   21,600   31,357 

1114

 

WORLD HEALTH ENERGY HOLDINGS, INC.INC .

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

B.Balances with related parties and officers:

       
  As of September 30,  As of December 31, 
  2021  2020 
       
Other current assets  1,634   - 
Other accounts liabilities  120,000   191,994 
Long term loan from related party  2,025,049   1,812,704 
Liability for employee rights upon retirement  115,550   95,451 

NOTE 6 – COMMITMENTS AND CONTINGENCIES

In December 16, 2020 the Company signed a lease agreement effective as from January 1, 2021, for office space in Herzliya, Israel for a period of 3 years with monthly payments of approximately $5,000 and an option to extend the agreement for an additional 1 year with monthly payments of approximately $5,500. As of September 30, 2021, the balance of the lease liability amounted to $221,261 and right-of-use asset amounted to $213,184.

On October 27, 2020 WHEN filed suit in State Court, Palm Beach County, Florida, against FSC Solutions, Inc. (“FSC”), Eli Gal Levy (“EL”) and Padem Consultants Sprl (collectively, the “Defendants”). The suit relates to the Stock Purchase Agreement entered into by WHEN with FSC and its shareholders, which included EL, pursuant to which WHEN acquired all of the issued and outstanding stock of FSC in exchange for the issuance of 70 billion shares of WHEN unregistered common stock. FSC was the putative owner of a software and trading platform which WHEN intended to use to enter into the on-line trading business. Subsequent to the completion of the acquisition, we determined that FSC did not have control over the trading platform and software we expected to acquire and operate. The Suit sought declaratory judgment to unwind the FSC transaction and cancel the shares of WHEN common stock issued in the FSC transaction that are still outstanding.

A hearing was set for January 6, 2021 whereupon mediation was ordered. The Company has been in discussions with EL to resolve this issue.

12

WORLD HEALTH ENERGY HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

 

NOTE 75SUBSEQUENT EVENTS

 

1.A.Following On October 25, 2022, the effectivenessCompany exercised the option to acquire such additional shares of CrossMobile and following such exercise, the Company holds approximately 51% of CrossMobile’s outstanding share capital on a fully diluted basis. In consideration for the exercise of the Amendment referred to in Note 3,option, the Company issuedshall issue to CrossMobile 387,000,000,000 10,000,000,000shares of the Company’s common stock to UCG, Inc., a Florida corporation owned jointly by Gaya Rozensweig and George Baumeohl, the Company’s directors. upon the automatic conversion of all 3,870,000 stock.outstanding shares of the Company’s Series B Preferred Shares issued in April 2020 in connection with the acquisition of RNA, Ltd. From UCG, Inc. The terms of the Series B Preferred Stock are described in Note 1B above.
B.Between October 1, 2021 and the filing of this report the Company received additional subscription gross proceeds of $216,000 from the 2021 Private Placement and in respect thereof will issue 2,160,000,000 shares of Common Stock and warrants, exercisable for a two yearperiod, for an additional 2,160,000,000 shares of Common Stock exercisable at a per share exercise price of $0.0002.
C.On November 10, 2021, the Company entered into an agreement with a consultant with a term of 12 months under which it undertook to issue to the Consultant restricted stock for services rendered during the initial six months, representing $150,000 value of the stock based on a 10 day moving average. Following a public offering of its stock the Company undertook to pay to the Consultant $15,000 per month.

 

1315

 

ITEM 2.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Forward-Looking Statements

 

The following discussion should be read in conjunction with the financial statements and related notes contained elsewhere in this Quarterly Report on Form 10-Q, as well as our Annual Report on Form 10-K for the fiscal year ended December 31, 20202021 as filed with the Securities and Exchange Commission (the “SEC”) on April 15, 2021.14, 2022. Certain statements made in this discussion are “forward-looking statements” within the meaning of the private securities litigation reform act of 1995,. These statements are based upon beliefs of, and information currently available to, the Company’s management as well as estimates and assumptions made by the Company’s management. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. When used herein, the words “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “future,” “intend,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue” or the negative of these terms and similar expressions as they relate to the Company or the Company’s management identify forward-looking statements. Such statements reflect the current view of the Company with respect to future events and are subject to risks, uncertainties, assumptions, and other factors, including the risks relating to the Company’s business, industry, and the Company’s operations and results of operations and the effects that the COVID-19 outbreak, or similar pandemics, could have on our business. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned.

 

The full extent to which the COVID-19 pandemic may directly or indirectly impact our business, results of operations and financial condition will depend on future developments that are uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements, and although there is currently no major impact, there may be changes to those estimates in future periods. Actual results may differ from these estimates.

 

Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

 

Our financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). These accounting principles require us to make certain estimates, judgments and assumptions. We believe that the estimates, judgments and assumptions upon which we rely are reasonable based upon information available to us at the time that these estimates, judgments and assumptions are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods presented. Our financial statements would be affected to the extent there are material differences between these estimates and actual results. The following discussion should be read in conjunction with our financial statements and notes thereto appearing elsewhere in this report.

 

14

General Overview

 

World Health Energy Holdings, Inc. (“WHEN”we” “us” “our” the “Company” or “WHEN”) WHEN is a diversified energy, health, and cybersecurity technology company. On April 27, 2020, WHEN completed a reverse triangular merger pursuant to the Agreement and Plan of Merger (the “Merger Agreement”) among the Company, R2GA, Inc., through itsa Delaware corporation and a wholly owned subsidiariessubsidiary of the Company (“Sub”), UCG, Inc., a Florida corporation (“Seller”), SG 77 Inc., a Delaware corporation and wholly-owned subsidiary of Seller (“SG”), and RNA LtdLtd., an Israeli company and a wholly owned subsidiary of SG (“RNA”),. Under the terms of the Merger Agreement, R2GA merged with and into SG, with SG remaining as the surviving corporation and a wholly-owned subsidiary of the Company (the “Merger”). The Merger became effective as of April 29, 2020. Each of Gaya Rozensweig and George Baumeohl, directors of the Company, are also the sole shareholders and directors of UCG.

16

RNA is primarily a research and development company that has been performing software design services in the field of cybersecurity. SG is primarily engaged in data securitythe marketing and analytics and provides intelligent security software and services to enterprises and individuals worldwide WHEN leverages artificial intelligence (“AI”) and machine learning to deliver innovative solutions in the areasdistribution of cybersecurity safety focusing onrelated products. In anticipation of the areastransaction contemplated under the Merger Agreement, SG was formed and all of endpoint security, endpoint managementthe cybersecurity rights and encryption.interests held by UCG, including the share ownership of RNA, were assigned to SG.

 

AsFollowing the digital transformationclosing, each of enterprises continues to advance, workforces are becoming more dispersedSG 77 and mobile, and data and applications are increasingly migrating to the cloud. As part of this trend, the number of connected endpoints is growing rapidly, as is their complexity and the volume of data that they process and store. These endpoints, which include smartphones, laptops, desktops, servers, vehicles, industrial equipment and other connected devices in the Internet of Things (“IoT”), are increasingly a target for cyber adversaries. The COVID-19 pandemic has accelerated the decentralizationRNA became wholly-owned subsidiaries of the workplace prompting many enterprises to shift to substantially remote and mobile work models. At the same time, the threat environment has become increasingly hostile as the number of adversaries grows and the scale and sophistication of their attacks, increasingly focused on the endpoint, continue to develop.Company.

 

Recent Developments

(i) As previously disclosed, WHEN completed the acquisition of a 26% equity interest in CrossMobile Sp. z o.o, a company formed under the laws of Poland (“CrossMobile”). On March 22, 2022 the Company, CrossMobile and the shareholders of CrossMobile entered into an Investment Agreement (the “Agreement”) pursuant to which the Company is to purchase 26% of the outstanding common share capital of CrossMobile on a fully diluted basis, in consideration of the issuance by the Company to CrossMobile of 10,000,000,000 restricted shares of Company common stock (the “Initial Investment”). Prior to the closing, Mr. Giora Rozensweig, the Company CEO, held 40.67% and Mr. George Baumeohl, a director, held 3.33%, of the issued preferred share capital of CrossMobile). The landscapepreferred share capital of increasing vulnerability has created opportunitiesCrossMobile provides certain privileges, including the right to participate in CrossMobile shareholder meetings at a rate of two votes for secure communications platforms, endpoint cybersecurityeach preferred share and management solutions, analytic toolspreference as to distribution of dividends at a rate equal to twice the dividends distributed to the holders of the common shares in CrossMobile.

CrossMobile filed an application with the Polish Companies Registrar on June 22, 2022 to increase its share capital in order to effectuate the issuance to WHEN of the CrossMobile ordinary shares representing 26% of the CrossMobile equity interest to WHEN and related services that help enterprisesto register the issuance to CrossMobile of the 10,000,000,000 WHEN shares in consideration thereof. The Companies Registrar approved the requested actions on July 22, 2022 and individualspublished on August 1, 2022. The approval and registration by the Polish Companies Registrar is required under local law for CrossMobil to secure their connected endpoints. Our software specializes in data protection, threat detection and response. Our product offerings enable enterprisesissue to protect data stored on premises andWHEN the CrossMobile ordinary shares representing 26% of CrossMobile. In anticipation of the approval of the increase in the cloud, confidential data belongingshare capital of CrossMobile, WHEN issued to customers, financial records, strategicCrossMobile on July 13, 2022 the 10,000,000,000 WHEN shares. Following the closing of the Initial Investment, Ms. Gaya Rozensweig, a Company director, was appointed to the CrossMobile board of directors and product plansthe combined holdings of Giora Rozensweig and other intellectual property and,WHEN, afford them effective control of the majority of the outstanding voting capital of CrossMobile

Through January 22, 2024, the Company has the option to purchase additional shares of CrossMobile, such that following such additional purchase, the Company would hold approximately 51% of CrossMobile’s outstanding share capital on a parental or guardian level,fully diluted basis. In the event the Company elects to monitor minor children’s cyber activities.exercise the option, the Company shall issue such number of restricted shares of common stock of the Company calculated based on pre-money valuation of CrossMobile as determined by an independent appraiser agreed between the Company and CrossMobile. On October 25, 2022, the Company exercised the option to acquire such additional shares of CrossMobile and the Company now holds approximately 51% of CrossMobile’s outstanding share capital on a fully diluted basis. In consideration for the exercise of the option, the Company shall issue to CrossMobile 10,000,000 shares of the Company’s common stock.

Business Overview of the CrossMobile Transaction

 

We believe that the COVID-19 pandemic, which continues to impact allacquisition of society has increasedCrossMobile provides an opportunity in our long-term opportunity to help our customers protect their dataevolution and detect threats. Companies around the world now have employees working remotely from potentially vulnerable home networks, accessing critical on-premises data storages and infrastructure through VPNs and sharing information in cloud data stores. We believe this trend is likely to continueprovides us with a strong foothold in the long-term and that we are striving to capitalize onEuropean market. CrossMobile is part of a limited group of licensed mobile virtual network operators (MVNO) in the opportunity ahead.

Product Offerings & Revenue Model

Our product offerings are comprised of two principal segments, one targeting for commercial enterprises (B2B) and one for the individual users (B2C).

B2B Offerings—The B2B Cybersecurity system software development and implementation program focused on innovative solutions for the constantly evolving cyber challenges of businesses, non-governmental organizations (NGO’s) and governmental entities.

We recently launched OTOGRAPH, our comprehensive cybersecurity and information security system, to enable business enterprises to monitor, analyze and prevent suspicious or harmful behavior on corporate networks and connected devices. The OTOGRAPH is designed to analyze and prevent internal or external abuse or abnormal activity on enterprise devices, such as PCs, mobile phones, servers or any other OS-based IOT device.European Union.

  

The rapid transitionglobal telecom market was valued at $1.6 trillion in 2020 and is expected to opengrow at 5.4% Compound Annual Growth Rate (CAGR) through 20281. The global cybersecurity market was valued at $140 billion in 2021 and cloud-based remote workforce has exposed businessesis expected to reach $376 billion by 20292. By combining the telecom focus with our existing cyber security product offering, our plan is to bring to market a new standard of service in value added telecom and organizations across the world to higher risks of cyber-attackssecurity solutions for B2B and information security breaches. To enable businesses to better protect their data and workflow, we developed a Business Behavioral Analysis (BBA) system that enables business leaders to track all activity from any given location on a one-stop dashboard. Developed over the past two years, OTOGRAPH provides aggregated data and a wide variety of real-time analytics such as real time monitoring of online behavior, applications and system behavior, data breaches, internal and external connections analytics, productivity analysis and psycholinguistic analysis. Corporations and organizations can then use the dashboard to detect suspicious human or device activities that put their company at risk.B2C customers alike.

 

1 Global Telecom Services Market Size Report, 2021-2028. (2022). Retrieved 21 August 2022, from https://www.grandviewresearch.com/industry-analysis/global-telecom-services-market

2 Insights, F. (2022). With 13.4% CAGR, Global Cyber Security Market Size to Surpass USD 376.32 Billion in 2029. Retrieved 21 August 2022, from https://www.globenewswire.com/news-release/2022/06/14/2461786/0/en/With-13-4-CAGR-Global-Cyber-Security-Market-Size-to-Surpass-USD-376-32-Billion-in-2029.html

1517

 

 

OTOGRAPH was developed based on a state of the art intelligence technology combined with AI technology that processes and analyzes massive amounts of behavioral and communication data and enables organizations to make real time accurate preventive assessments and decisions to protect company assets and ensure operational efficiency.OTOGRAPH deploys a unique Business Behavioral Analysis (BBA) machine learning software. Behavioral digital data is extracted from all endpoint devices that are connected to the company’s network infrastructure – whether physically, wirelessly or remotely. The data is processed and analyzed to learn and to reveal the unique digital behavioral pattern of the organization as a whole and of every endpoint or individual.

 

OTOGRAPH sets baselinesBy combining the current solutions of normal patternsthese two divisions, WHEN expects to commercialize a new standard of service in value added telecom and security solutions for each,B2B and constantly searches for anomalies – deviations from those expected patterns. The anomalies are detected automatically and instantly, categorized by their type and generate push alerts which are sent to the business leader’s dashboard and enabling him to respond to the threat.

B2C Cybersecurity —The B2C Cybersecurity division targets families concerned with external cyber threats and exposures in addition to monitoring a child’s behavioral patterns that may alert parents to potential tragedies caused by cyber bullying, pedophiles, other predators, and depression.customers alike.

 

Our go-to-market strategy focuses principally on generating revenue from software, servicesstrategic plan for the next 12 months includes the following

a.Integrating IT infrastructure with MNO Telecom operator in Poland on standard packages of Voice, SMS and Data service. (name of Telekom operator will be released in separate announcement)
b.Finalizing tests of platform for sales and customer care. This platform will be based on in-house artificial intelligence systems to keep operating costs substantially below market
c.Start test of integration with and sales of Data packages

CrossMobile anticipates that it will be able to go live in December 2022 with the following:

a.Be in the air with standard packages of Voice, SMS and Data in Poland and International Roaming.
b.Generate first invoice for sales of standard packages of Voice, SMS and Data in Poland and International Roaming
c.Initiate cooperation with existing or build new MVNO Telecom operators similar to CrossMobile to fully optimize ROI on the investment made in people and IT Systems. Focus areas will be USA, UK, Asia Pacific and selected countries in Europe with high potential.

Key Financial Terms and licensing. We intend to sell substantially all of our products and services to distributors and resellers, which will sell to end-user customers, which we refer to in this report as our customers.Metrics

 

The following discussion summarizes the key factors our management believes are necessary for an understanding of our consolidated financial statements.

Other Corporate HoldingsRevenues

 

We currently also have the following subsidiaries.generate revenues primarily from software license fees.

 

FSC Solutions, Inc. On June 26, 2015, we entered into a Stock Purchase Agreement (the “Agreement”) with FSCResearch and its shareholders which included Uri Tadelis, our former Chief Executive Officer and Director and our former Directors Chaim J. Lieberman and Gal Levy. The Agreement was effective as of July 1, 2015 which served as the closing date for the acquisition. Pursuant to the terms of the Agreement, we acquired all of the capital stock of FSC in exchange for the issuance of 70 billion shares of our unregistered common stock with the possibility of the issuance of an additional 130 Billion common shares upon FSC meeting certain milestones as outlined in the Agreement. Upon completion of the acquisition of FSC, we intended to employ FSC’s software and trading platform to enter the on-line trading industry. Subsequent to the completion of the acquisition, we determined that FSC did not have control over the trading platform and software we expected to acquire and operate. Please refer to Item 1, Part II, of this report.Development Expenses

 

World Health Energy, Inc. World Health Energy, Inc. owns an algae-tech business whose primary focus wasThe process of researching and developing our product candidates is lengthy, unpredictable, and subject to many risks. We expect to continue incurring substantial expenses through 2023 as we continue to develop our product offerings and adapt them to our new MVNO business. We are unable, with any certainty, to estimate either the productioncosts or the timelines in which those expenses will be incurred..

18

Our research and development costs include costs are comprised of:

● internal recurring costs, such as personnel-related costs (salaries, employee benefits, equity compensation and other costs), materials and supplies, facilities and maintenance costs attributable to research and development functions; and

● fees paid to external parties who provide us with contract services.

General and Administrative Expenses

General and administrative expenses consist primarily of algae using their proprietary GB3000 growth system. salaries, employee benefits, equity compensation, and other personnel-related costs associated with executive, administrative and other support staff. Other significant general and administrative expenses include the costs associated with professional fees for accounting, auditing, insurance costs, consulting and legal services, along with facility and maintenance costs attributable to general and administrative functions.

Financial Expenses

Financial expenses consist primarily impact of exchange rate derived from re-measurement of monetary balance sheet items denominated in non-dollar currencies. Other financial expenses include bank’s fees and interest on long term loans.

Comparison of the Three Months Ended September 30, 2022 to the Three Months Ended September 30, 2021

The system quickly and efficiently grows algaefollowing table presents our results of operations for the production of biofuelsthree months ended September 30, 2022 and food protein. We also sought to produce and market high-quality, low-cost B100 biodiesel. Though, we believe that the Company has been successful in demonstrating the effectiveness of the GB3000 system on a small-scale the Company has not yet been able to raise the necessary capital to implement their technologies on a commercial scale.2021

  Three Months Ended 
  September 30 
  2022  2021 
       
Revenues  23,726   33,717 
Operating Expenses        
Research and development expenses  (111,570)  (120,701)
General and administrative expenses  (106,828)  (466,847)
Share based compensation expenses  (4,529,664)  (1,459,120)
Operating loss  (4,724,336)  (2,012,951)
Financing income (expenses), net  8,881  (19,519)
Net loss  (4,715,455)  (2,032,470)

Revenues. Revenues for the three months ended September 30, 2022 and 2021 were $23,726 and $33,717, respectively. Revenues were comprised primarily of software license fees. The decrease in revenues is primarily related to efforts we undertook in the 2022 period to refocus our resources on the CrossMobile transaction.

Research and Development. Research and development expenses consist of salaries and related expenses, consulting fees, service providers’ costs, related materials and overhead expenses. Research and development expenses decrease from $120,701 in the three months ended September 30, 2021 to $111,570 during the corresponding period in 2022. The decrease resulted from decrease in salaries and related expenses offset by increase in consulting fees.

General and Administrative Expenses. General and administrative expenses consist primarily of salaries and related expenses and other non-personnel related. General and administrative expenses decreased from $466,847 for the three months ended September 30, 2021 to $106,828 during the corresponding period in 2022. The decrease resulted primarily from decrease in professional services expenses.

1619

 

 

Corporate Structure (Diagram)Financing Expenses, Net. Financing expenses, net for the three months ended September 30, 2021 amounted to $19,519. Financing income, net for the three months ended September 30, 2022 amounted to $8,881. The decrease is mainly due to currency exchange differences between the Dollar and the New Israeli Shekel.

Net Loss. Net loss for the three months ended September 30, 2022 was $4,715,455 and is primarily attributable to non-cash share based compensation expense of $4,529,664, research and development and general and administrative expenses.

Comparison of the Nine Months Ended September 30, 2022 to the Nine Months Ended September 30, 2021

 

The corporate structurefollowing table presents our results of operations for the WHEN Group is reflected below in this diagramthree months ended June 30 2022 and 2021

 

  Nine Months Ended 
  September 30 
  2022  2021 
       
Revenues  67,480   115,167 
Operating Expenses        
Research and development expenses  (354,593)  (374,561)
General and administrative expenses  (377,168)  (736,501)
Share based compensation expenses  (8,474,989)  (1,459,120)
Operating loss  (9,139,270)  (2,455,015)
Financing income (expenses), net  45,515   (50,435)
Net loss  (9,093,755)  (2,505,450)

 

Revenues. Revenues for the nine months ended September 30, 2022 and 2021 were $67,480 and $115,167, respectively. Revenues were comprised primarily of software license fees. The decrease in revenues is primarily related to efforts we undertook in the 2022 period to refocus our resources on the CrossMobile transaction

 

Recent DevelopmentsResearch and Development. Research and development expenses consist of salaries and related expenses, consulting fees, service providers’ costs, related materials and overhead expenses. Research and development expenses decreased from $374,561 for the nine months ended September 30, 2021 as compared to $354,593 during the corresponding period in 2022. The decrease resulted primarily from decrease in salaries and related expenses.

General and Administrative Expenses. General and administrative expenses consist primarily of salaries and related expenses and other non-personnel related expenses such as legal expenses. General and administrative expenses decreased from $736,501 for the nine months ended September 30, 2021 as compared to $377,168 in 2022 during the corresponding period in 2022. The decrease resulted primarily from decrease in professional services expenses.

Financing Expenses, Net. Financing expenses, net for the nine months ended September 30, 2021 amounted to $50,435. Financing income, net for the nine months ended September 30, 2022 amounted to $45,515. The increase is mainly due to currency exchange differences between the Dollar and the New Israeli Shekel.

Net Loss. Net loss for the nine months ended September 30, 2022 was $9,093,755 and is primarily attributable to non-cash share based compensation expense of $8,474,989, research and development and general and administrative expenses.

Financial Condition, Liquidity and Capital Resources

 

On June 21,Liquidity is the ability of an enterprise to generate adequate amounts of cash to meet its needs for cash requirements. At September 30 and 2022 and 2021, Company’s stockholders approvedwe had current assets of $371,280 and $355,188 respectively, and total assets of $5,472,583 and $622,735 respectively. The increase in total assets is primarily due to an amendmentincrease in our investments and cash balance. We had current liabilities of $539,617 as compared to $1,297,427 as of September 30, 2022 and 2021, respectively and total liabilities of $2,830,399 as compared to $3,649,405 as of September 30, 2022 and 2021, respectively. The decrease is mainly attributed to the Company’s Certificatedecrease in the balance of Incorporation (the “Reverse Stock Split Certificateother accounts liabilities and right of Amendment”)use liabilities arising from operating lease offset by increase in order to effectaccounts payable.

20

At September 30, 2022, we had a reverse stock splitcash balance of the Company’s common stock pursuant to a range of between 1,000-to-1 and 15,000-to-1 (the “Reverse Stock Split”), when and as determined by the Company’s Board of Directors. Pursuant$111,436 compared to the Reverse Stock Split, each one thousand or fifteen thousand sharescash balance of common stock, or any other figure within that range,$46,022 as shall be determined by the Board of Directors at a later time, will be automatically converted, without any further action by the stockholders, into one share of common stock. The Reverse Stock Split Certificate of Amendment will be effective upon receipt of approval from the Financial Industry Regulatory Authority (“FINRA”) for the Reverse Stock Split and the filing with the Secretary of the State of Delaware. As of the date of this report, the Board of Directors has not determined any particular ratio for the Reverse Stock Split andDecember 31, 2021. We have no application has been presented to FINRAcash equivalents.

 

On June 21, 2021, the BoardAt September 30, 2022, we had a negative working capital of Directors and the Company’s stockholders adopted, the 2021 Equity Incentive Plan (the “2021 Plan”) pursuant to which 50 billion shares$168,337 as compared with a working capital of common stock have been reserved for issuance to employees, including officers, directors and consultants. The Company undertook to issue under the 2021 Plan options for a total of 16,800,000,000 shares of the Company’s common stock$547,972 at a per share exercise price of $0.001 per share. The options can only be issued following the adoption by the Board of the of the Israeli Appendix to the 2020 Incentive Stock Plan and its submission to the Israel Tax Authorities.December 31, 2021.

 

Between AugustIn January 2022, the Company received $34,000 from an investor who entered into a subscription agreement with the Company in October 2021 for an investment of $200,000 to be remitted to the Company in periodic three month instalments, representing the second agreed upon instalment amount. In accordance with the terms of his subscription agreement, we issued to the investor a total 340,000,000 shares of our common stock and October 2021,he is entitled to warrants for an additional 680,000,000 shares of our common stock. In May 2022, we received $40,000 from the same investor, representing the third agreed upon instalment amount to be remitted to the Company. In accordance with the terms of his subscription agreement, we issued to the designees of such investor a total 400,000,000 shares of our common stock and he is entitled to warrants for an additional 800,000,000 shares of our common stock.

During March 2022, the Company and certain investors entered into subscription agreements for a private placement of units of the Company securitiesin an aggregated amount of $500,000, where each unit (a “Unit” and collectively the “Units”) is comprised of (i) one (1) share of the Company’s Common Stock and (ii) one common stock purchase warrant to purchase an additional share of the Company’s Common Stock through the second anniversary thereof at a per share exercise price of $0.0002. The price per unit is $0.0001. Subscription agreements for an aggregate of $900,000 provide that the investors are to remit the subscription proceeds at the time of investment and in three month intervals thereafter, in each case in amounts equal to 20% of their committed amounts. Subscription agreements for a total of $170,000 were remitted at the time of execution. Through September 30, 2021, the Company received a total of $170,000 from these subscription proceeds and inIn consideration thereof issued 1,700,000,000the holders are entitled to 5,000,000,000 shares of common stockCommon Stock and warrants for an additional 1,700,000,0005,000,000,000 shares of common stock. From October 1, 2021 through the filingCommon Stock, of this report the Company received an additional $216,000 from these subscription proceeds and issued 2,160,000,000which to date 2,500,000,000 shares of common stockCommon Stock and warrants for an additional 2,160,000,0002,500,000,000 shares of common stock.Common Stock have been issued.

 

17

On October 7, 2021,During May 2022, the Company filedentered into subscription agreements with two investors for a private placement of units of the Company securities in an amendment (the “Amendment”aggregated amount of $250,000, where each unit (a “Unit” and collectively the “Units”) to its Certificateis comprised of Incorporation, as amended, to increase the Company’s authorized(i) one (1) share capital and to change the par value of the Company’s Common Stock. The Amendment increased the Company’s authorized share capital to 750,000,000,000 shares ofStock and (ii) two common stock (from 110,000,000,000 shares) and changed the par value of the common stockpurchase warrants to $0.00001 perpurchase an additional share (from $0.0007).

Following the effectiveness of the Amendment, the Company issued 387,000,000,000 shares of the Company’s common stockCommon Stock through the second anniversary thereof at a per share exercise price of $0.0003. The price per unit was $0.0003. In consideration thereof the holders are entitled to UCG, Inc., a Florida corporation owned jointly by Gaya Rozensweig and George Baumeohl, the Company’s directors. upon the automatic conversion of all 3,870,000 outstanding833,333,334 shares of the Company’s Series B Preferred Shares issued in April 2020 in connection with the acquisition of RNA, Ltd. From UCG, Inc.

On November 10, 2021, the Company entered intoCommon Stock and warrants for an agreement with a consultant with a term of 12 months under which it undertook to issue to the Consultant restricted stock for services rendered during the initial six months, representing $150,000 value of the stock based on a 10 day moving average. Following a public offering of its stock the Company undertook to pay to the Consultant $15, 000 per month.

In November 2021, the Company issued to a consultant a total of 5,700,000,000additional 1,666,666,668 shares of stock for services provided. TheCommon Stock, of which to date the shares were issued under the terms of an investment agreement entered into as of October 2018

Comparison of the Three Months Ended September 30, 2021 to the Three Months Ended September 30, 2020

The following table presents our results of operations for the three months ended September 30 2021Common Stock and 2020

  Three Months Ended 
  September 30 
  2021  2020 
       
Revenues  33,717   24,798 
Operating Expenses        
Research and development expenses  (120,701)  (181,175)
General and administrative expenses  (1,925,967)  (109,466)
Operating loss  (2,012,951)  (265,843)
Financing income (expenses), net  (19,519)  (2,307)
Net loss  (2,032,470)  (268,150)

Revenues. Revenues for the three months ended September 30, 2021 and 2020 were $33,717 and $24,798, respectively. Revenues were comprised primarily of software license fees.

18

Research and Development. Research and development expenses consist of salaries and related expenses, consulting fees, service providers’ costs, related materials and overhead expenses. Research and development expenses decreased from $181,175 for the three months ended September 30, 2020 to $120,701 during the corresponding period in 2021. The decrease resulted primarily from decrease in salaries and related expenses associated with our development activities.

General and Administrative Expenses. General and administrative expenses consist primarily of salaries and related expenses, share based compensation for service providers and other non-personnel related expenses such as legal expenses. General and administrative expenses increased from $109,466 for the three months ended September 30, 2020 to $1,925,967 in 2021. The increase is primarily attributable to the increase in share based compensation to service providers, salaries and related expenses, professional services other non-personnel related expenses.

Financing Expenses, Net. Financing income, net for the three months ended September 30, 2020 amounted to $2,307. Financing expenses, net for the three months ended September 30, 2021 amounted to $19,519. The increase is mainly due to currency exchange differences between the Dollar and the New Israeli Shekel.

Net Loss. Net loss for the three months ended September 30, 2021 was $2,032,470 and is primarily attributable to research and development, share based compensation and general and administrative expenses.

Comparison of the Nine Months Ended September 30, 2021 to the Nine Months Ended September 30, 2020

The following table presents our results of operations for the three months ended September 30 2021 and 2020

  Nine Months Ended 
  September 30 
  2021  2020 
       
Revenues  115,167   52,906 
Operating Expenses        
Research and development expenses  (374,561)  (328,529)
General and administrative expenses  (2,195,621)  (227,525)
Operating loss  (2,455,015)  (503,148)
Financing income (expenses), net  (50,435)  6,925 
Net loss  (2,505,450)  (496,223)

Revenues. Revenues for the nine months ended September 30, 2021 and 2020 were $115,167 and $52,906, respectively. Revenues were comprised primarily of software license fees.

Research and Development. Research and development expenses consist of salaries and related expenses, consulting fees, service providers’ costs, related materials and overhead expenses. Research and development expenses increased from $328,529 for the nine months ended September 30, 2020 as compared to $374,561 during the corresponding period in 2021. The increase resulted primarily from increase in salaries and related expenses associated with our development activities.

19

General and Administrative Expenses. General and administrative expenses consist primarily of share based compensation for service providers, salaries and related expenses and other non-personnel related expenses such as legal expenses. General and administrative expenses increased from $227,525 for the nine months ended September 30, 2020 as compared to $2,195,621 in 2021. The increase is primarily attributable to the increase in share based compensation, salaries and related expenses, professional services other non-personnel related expenses.

Financing Expenses, Net. Financing income, net for the nine months ended September 30, 2020 amounted to $6,925 Financing expenses, net for the nine months ended September 30, 2021 amounted to $50,435. The increase is mainly due to currency exchange differences between the Dollar and the New Israeli Shekel.

Net Loss. Net loss for the nine months ended September 30, 2021 was $2,505,450 and is primarily attributable to research and development, share based compensation and general and administrative expenses.

Financial Condition, Liquidity and Capital Resources

Liquidity is the ability of an enterprise to generate adequate amounts of cash to meet its needs for cash requirements. At September 30, 2021 and 2020, we had current assets of $355,188 and $419,800 respectively, and total assets of $622,735 and $441,849 respectively. The increase in total assets is due to the increase other current assets and in right of use asset arising from operating lease. We had current liabilities of $1,297,427 as compared to $458,609 as of September 30, 2021 and 2020, respectively and total liabilities of $3,649,405 as compared to $2,048,059 as of September 30, 2021 and 2020, respectively. The increase is mainly attributed to the increase in the balance of employees and related institutions, accrued expenses ,right of use liabilities arising from operating lease and increase in loans received from a related party.

At September 30, 2021, we had a cash balance of $53,369 compared to the cash balance of $359,949 as of December 31, 2020. Wewarrants have no cash equivalents.

At September 30, 2021, we had a working capital deficiency of $942,239 as compared with a working capital deficiency of $115,945 at December 31, 2020.been issued.

 

We expect that our existing cash and cash equivalents as well as expected revenuesperiodic remittances from subscription proceeds will enable us to fund our operations and capital expenditure requirements through year end 2021.March 2023. Our requirements for additional capital during this period will depend on many factors.factors, including the amounts necessary to bring the CrossMobile operations live by December 2022.

 

We may seek to raise any necessary additional capital through a combination of private or public equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements. To the extent that we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights, future revenue streams, or product candidates or to grant licenses on terms that may not be favorable to us. If we raise additional capital through private or public equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders’ rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.

 

20

Going Concern

 

The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern. We have a stockholders’ deficitequity of $3,026,670$2,642,184 and a negative working capital deficiency of $942,239$168,337 at September 30, 20212022 as well as negative operating cash flows. These conditions raise substantial doubt about our ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.

 

21

Off-Balance Sheet Arrangements We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the Company’s financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.

ITEM 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not applicable.

ITEM 4.CONTROLS AND PROCEDURES

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures.

 

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) that are designed to ensure that information required to be disclosed by us in reports that we file under the Exchange Act is recorded, processed, summarized and reported as specified in the SEC’s rules and forms and that such information required to be disclosed by us in reports that we file under the Exchange Act is accumulated and communicated to our management, including our Interim Chief Executive Officer, to allow timely decisions regarding required disclosure. Management, with the participation of our Interim Chief Executive Officer, performed an evaluation of the effectiveness of our disclosure controls and procedures as of SeptemberJune 30, 2021.2022. Based on that evaluation, our management, including our Interim Chief Executive Officer, concluded that our disclosure controls and procedures were not effective as of September 30, 2021.2022.

 

Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. As disclosed in Item 9A of our Annual Report on Form 10-K for the year ended December 31, 2020,2021, our management concluded that our internal control over financial reporting was not effective at December 31, 2020.2021. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. The limitation of the Company’s internal control over financial reporting was due to the applied risk-based approach which is indicative of many small companies with limited number of staff in corporate functions. The identified weakness were:

 

Material Weakness – We did not maintain effective controls over certain aspects of the financial reporting process because we (i) lacked a sufficient complement of personnel with a level of accounting expertise and an adequate supervisory review structure that is commensurate with our financial reporting requirements and (ii) we lacked controls over the disclosure of our business operations.
  
lack of segregation of duties Significant Deficiencies – Inadequate segregation of duties.

 

Our management believes the weaknesses identified above have not had any material effect on our financial results.

 

21

We expect to be materially dependent upon third parties to provide us with accounting consulting services for the foreseeable future which we believe will mitigate the impact of the material weaknesses discussed above. Until such time as we have a chief financial officer with the requisite expertise in U.S. GAAP and establish an audit committee and implement internal controls and procedures, there are no assurances that the material weaknesses and significant deficiencies in our disclosure controls and procedures will not result in errors in our financial statements which could lead to a restatement of those financial statements.

 

Changes in Internal Controls over Financial Reporting.

 

Except for the material weakness and associated remediation plan, , there have been no changes in our internal control over financial reporting during the fiscal quarter ended September 30, 20212022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

22

PART II—OTHER INFORMATION

ITEM 1.LEGAL PROCEEDINGS

 

ITEM 1. LEGAL PROCEEDINGS

On October 27, 2020 WHEN filed suit in State Court, Palm Beach County, Florida, against FSC Solutions, Inc. (“FSC”), Eli Gal Levy (“EL”) and Padem Consultants Sprl (collectively, the “Defendants”). The suit relates to the Stock Purchase Agreement entered into by WHEN with FSC and its shareholders, which included EL, pursuant to which WHEN acquired all of the issued and outstanding stock of FSC in exchange for the issuance of 70 billion shares of WHEN unregistered common stock. FSC was the putative owner of a software and trading platform which WHEN intended to use to enter into the on-line trading business. Subsequent to the completion of the acquisition, we determined that FSC did not have control over the trading platform and software we expected to acquire and operate. The Suit sought declaratory judgment to unwind the FSC transaction and cancel the shares of WHEN common stock issued in the FSC transaction that are still outstanding.

 

A hearing was set for January 6, 2021 whereupon mediation was ordered. Mediation meetings were held but no resolution was reached. The Florida lawsuit is currently pending.

On or about, January 19, 2022, EL filed a lawsuit in the Delaware Court of Chancery seeking to remove the restrictive legend from all the shares of Common Stock held by EL (the “2022 Lawsuit”), which are approximately 23,000,000,000 shares. The Company retained the services of Delaware counsel and has beenmoved to dismiss or stay the 2022 Lawsuit in discussionfavor of the previously filed Florida lawsuit, which involves the same parties and same issues. The Company’s motion to dismiss was denied. The Company answered the complaint, denying all allegations, and filed a counterclaim against EL and other third party defendants in September 2022. EL filed a motion to dismiss the counterclaim, which is currently pending.

On June 24, 2022 the Company filed an amended complaint in Palm Beach County, Florida (CASE NO. 50-2020- CA-011735), alleging violation of Fla. Stat. 517.301, seeking declaratory relief with regard to the status of the shares held and transferred by EL, and seeking a temporary injunction with regard to resolvethe transfer of any subject shares. The suit was dismissed without prejudice. The Company is currently not pursuing the lawsuit in Florida as the Company’s counterclaim in Delaware referred to above seeks substantially the same redress.

The Company intends to continue to vigorously pursue this issue.action and avail itself of all options lawfully available to it.

 

From time to time we may become involved in various legal proceedings that arise in the ordinary course of business, including actions related to our intellectual property. Although the outcomes of these legal proceedings cannot be predicted with certainty, we are currently not aware of any such legal proceedings that arise in the ordinary course of business, including actions related to our intellectual property. Although the outcomes of these legal proceedings cannot be predicted with certainty, we are currently not aware of any such legal proceedings or claims that we believe, either individually or in the aggregate, will have a material adverse effect on our business, financial condition, or results of operations.

ITEM 1A.RISK FACTORS

ITEM 1A. RISK FACTORS

 

An investment in the Company’s Common Stock involves a number of very significant risks. You should carefully consider the risk factors included in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2020,2021, as filed with the SEC on April 15, 2021,14, 2022, in addition to other information contained in our reports and in this quarterly report in evaluating the Company and its business before purchasing shares of our Common Stock. There have been no material changes to our risk factors contained in our Annual Report on Form 10-K for the year ended December 31, 2020.2021.

22

ITEM 2.UNREGISTERED SALES OF SECURITIES AND USE OF PROCEEDS

 

None.ITEM 2. UNREGISTERED SALES OF SECURITIES AND USE OF PROCEEDS

 

No Offerings in July- September?

We relied upon the exemption from the registration requirements of the Securities Act of 1933, as amended (the “Act”) by virtue of Section 4(a)(2) thereof and/or Regulation S promulgated by the SEC under the Act with respect to the issuance of such securities.

23

ITEM 3.DEFAULTS UPON SENIOR SECURITIES

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

ITEM 4.MINE SAFETY DISCLOSURES

ITEM 4. MINE SAFETY DISCLOSURES

 

None.

 

ITEM 5.OTHER INFORMATION:

ITEM 5. OTHER INFORMATION:

 

None.None

ITEM 6.EXHIBITS

 

ITEM 6. EXHIBITS

Exhibit Index:

 

31.1* Certification of Interim Chief Executive Officer (Principal Executive Officer and Principal Financial and Accounting Officer) pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934
   
32.1* Certification of Interim Chief Executive Officer (Principal Executive Officer and Principal Financial and Accounting Officer), as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
   
101.INS Inline XBRL Instance Document
   
101.SCH Inline XBRL Taxonomy Extension Schema
   
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase
   
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase
   
101.LAB Inline XBRL Taxonomy Extension Label Linkbase
   
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase
104Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Filed herewith

 

2324

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

WORLD HEALTH ENERGY HOLDINGS, INC.
(Registrant)
  
By:/s/ Giora Rozensweig
 Giora Rozensweig
 Interim Chief Executive Officer
 (Principal Executive Officer and Principal Financial and Accounting Officer)
  
Date:November 22, 202121, 2022

 

2425